New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study

Altay S., Yildirimturk O., Cakmak H. A., Askin L., Sinan U. Y., BEŞLİ F., ...More

ANATOLIAN JOURNAL OF CARDIOLOGY, vol.17, no.5, pp.353-361, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 5
  • Publication Date: 2017
  • Doi Number: 10.14744/anatoljcardiol.2016.7472
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.353-361
  • Keywords: new oral anticoagulants, atrial fibrillation, embolic complication, bleeding, ATRIAL-FIBRILLATION, STROKE INCIDENCE, CASE-FATALITY, RISK-FACTORS, MORTALITY, WARFARIN, THROMBOEMBOLISM, TRENDS
  • Recep Tayyip Erdoğan University Affiliated: Yes


Objective: New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). In this study, we aimed to evaluate the current patterns of NOACs treatment in Turkey. Moreover, demographic and clinical parameters and bleeding and/or embolic events under NOACs treatment were analyzed.